6C83 image
Deposition Date 2018-01-24
Release Date 2019-02-27
Last Version Date 2023-10-04
Entry Detail
PDB ID:
6C83
Title:
Structure of Aurora A (122-403) bound to inhibitory Monobody Mb2 and AMPPCP
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
2.55 Å
R-Value Free:
0.32
R-Value Work:
0.26
R-Value Observed:
0.26
Space Group:
P 21 21 21
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Aurora kinase A
Gene (Uniprot):AURKA
Chain IDs:A, B
Chain Length:285
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Mb2 Monobody
Chain IDs:C, D
Chain Length:93
Number of Molecules:2
Biological Source:synthetic construct
Ligand Molecules
Primary Citation
Allosteric modulation of a human protein kinase with monobodies.
Proc.Natl.Acad.Sci.USA 116 13937 13942 (2019)
PMID: 31239342 DOI: 10.1073/pnas.1906024116

Abstact

Despite being the subject of intense effort and scrutiny, kinases have proven to be consistently challenging targets in inhibitor drug design. A key obstacle has been promiscuity and consequent adverse effects of drugs targeting the ATP binding site. Here we introduce an approach to controlling kinase activity by using monobodies that bind to the highly specific regulatory allosteric pocket of the oncoprotein Aurora A (AurA) kinase, thereby offering the potential for more specific kinase modulators. Strikingly, we identify a series of highly specific monobodies acting either as strong kinase inhibitors or activators via differential recognition of structural motifs in the allosteric pocket. X-ray crystal structures comparing AurA bound to activating vs inhibiting monobodies reveal the atomistic mechanism underlying allosteric modulation. The results reveal 3 major advantages of targeting allosteric vs orthosteric sites: extreme selectivity, ability to inhibit as well as activate, and avoidance of competing with ATP that is present at high concentrations in the cells. We envision that exploiting allosteric networks for inhibition or activation will provide a general, powerful pathway toward rational drug design.

Legend

Protein

Chemical

Disease

Primary Citation of related structures